FRIULCHEM SPA has a total of 18 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2011. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Italy. Its main competitors in its focus markets pharmaceuticals, foods and drinks and organic fine chemistry are VEIJLEN N V, HERBONIS AG and ARATANA THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | Italy | 2 | |
#4 | Mexico | 2 | |
#5 | Australia | 1 | |
#6 | Brazil | 1 | |
#7 | Canada | 1 | |
#8 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Foods and drinks | |
#3 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Fodder | |
#4 | Heterocyclic compounds | |
#5 | Food shaping | |
#6 | Acyclic or carbocyclic compounds | |
#7 | Edible oils |
# | Name | Total Patents |
---|---|---|
#1 | Derrieu Guy | 9 |
#2 | Mazzola Giancarlo | 9 |
#3 | Coppi Germano | 6 |
#4 | Moiana Silvia | 6 |
#5 | Mazzola Disma | 4 |
#6 | Mazzola Disma Giovanni | 3 |
#7 | Perri Lidia | 2 |
#8 | Giancarlo Mazzola | 1 |
#9 | Guy Derrieu | 1 |
Publication | Filing date | Title |
---|---|---|
EP3468531A1 | Self-emulsifying lipid compositions | |
EP2890247A1 | Compositions for oral administration to animals, production methods thereof and uses of same | |
CA2883139A1 | Compositions for oral administration to animals, production methods thereof and uses of same | |
BR112014005909A2 | compositions for oral administration to animals, production methods and uses thereof | |
EP2755498A1 | Composition for oral administration to animals and production method | |
EP2710014A1 | Process for the synthesis of rifaximin | |
EP2574333A1 | N-acetylcysteine effervescent tablet and its therapeutical applications | |
WO2012155981A1 | New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby |